Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Short-term Investments: 2015-2024

Historic Short-term Investments for Zevra Therapeutics (ZVRA) over the last 5 years, with Dec 2024 value amounting to $35.7 million.

  • Zevra Therapeutics' Short-term Investments rose 310.53% to $145.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.1 million, marking a year-over-year increase of 310.53%. This contributed to the annual value of $35.7 million for FY2024, which is 44.65% up from last year.
  • Per Zevra Therapeutics' latest filing, its Short-term Investments stood at $35.7 million for FY2024, which was up 44.65% from $24.7 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Short-term Investments registered a high of $35.7 million during FY2024, and its lowest value of $16.9 million during FY2022.
  • In the last 3 years, Zevra Therapeutics' Short-term Investments had a median value of $24.7 million in 2023 and averaged $25.8 million.
  • Data for Zevra Therapeutics' Short-term Investments shows a peak YoY spiked of 46.08% (in 2023) over the last 5 years.
  • Zevra Therapeutics' Short-term Investments (Yearly) stood at $16.9 million in 2022, then spiked by 46.08% to $24.7 million in 2023, then surged by 44.65% to $35.7 million in 2024.